Glucagon Receptor Antagonist, Control
|
- $179 - $848
- Product name: Glucagon Receptor Antagonist, Control
- CAS: 362482-00-6
- MF: C21H23BrN2OS
- MW: 431.39
- EINECS:
- MDL Number:MFCD01344061
- Synonyms:Glucagon Receptor Antagonist, Control;4-bromo-N-[3-cyano-6-(2-methylbutan-2-yl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]benzamide;Glucagon Receptor Antagonist Inactive Control;Benzamide, 4-bromo-N-[3-cyano-6-(1,1-dimethylpropyl)-4,5,6,7-tetrahydrobenzo[b]thien-2-yl]-;4-bromo-N-[3-cyano-6-(1,1-dimethylpropyl)-4,5,6,7-tetrahydrobenzo[b]thien-2-yl]-benzamide
3 prices
Selected condition：
Brand
- AK Scientific
- Cayman Chemical
Package
- 1mg
- 5mg
- ManufacturerAK Scientific
- Product number1374CM
- Product descriptionGlucagonReceptorAntagonist,Control
- Packaging1mg
- Price$322
- Updated2021-12-16
- Buy
- ManufacturerCayman Chemical
- Product number21188
- Product descriptionGlucagon Receptor Antagonist Inactive Control
- Packaging1mg
- Price$179
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number21188
- Product descriptionGlucagon Receptor Antagonist Inactive Control
- Packaging5mg
- Price$848
- Updated2024-03-01
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| AK Scientific | 1374CM | GlucagonReceptorAntagonist,Control | 1mg | $322 | 2021-12-16 | Buy |
| Cayman Chemical | 21188 | Glucagon Receptor Antagonist Inactive Control | 1mg | $179 | 2024-03-01 | Buy |
| Cayman Chemical | 21188 | Glucagon Receptor Antagonist Inactive Control | 5mg | $848 | 2024-03-01 | Buy |
Properties
Boiling point :490.8±45.0 °C(Predicted)
Density :1.38±0.1 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :DMSO: Soluble
form :A crystalline solid
pka :11.83±0.40(Predicted)
Density :1.38±0.1 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :DMSO: Soluble
form :A crystalline solid
pka :11.83±0.40(Predicted)
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|